Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?
Standard
Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity? / Somaiah, N; Rothkamm, K; Yarnold, J.
in: CLIN ONCOL-UK, Jahrgang 27, Nr. 10, 21.06.2015, S. 570-578.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?
AU - Somaiah, N
AU - Rothkamm, K
AU - Yarnold, J
N1 - Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
PY - 2015/6/21
Y1 - 2015/6/21
N2 - The response of human normal tissues to radiotherapy fraction size is often described in terms of cellular recovery, but the causal links between cellular and tissue responses to ionising radiation are not necessarily straightforward. This article reviews the evidence for a cellular basis to clinical fractionation sensitivity in normal tissues and discusses the significance of a long-established inverse association between fractionation sensitivity and proliferative indices. Molecular mechanisms of fractionation sensitivity involving DNA damage repair and cell cycle control are proposed that will probably require modification before being applicable to human cancer. The article concludes by discussing the kind of correlative research needed to test for and validate predictive biomarkers of tumour fractionation sensitivity.
AB - The response of human normal tissues to radiotherapy fraction size is often described in terms of cellular recovery, but the causal links between cellular and tissue responses to ionising radiation are not necessarily straightforward. This article reviews the evidence for a cellular basis to clinical fractionation sensitivity in normal tissues and discusses the significance of a long-established inverse association between fractionation sensitivity and proliferative indices. Molecular mechanisms of fractionation sensitivity involving DNA damage repair and cell cycle control are proposed that will probably require modification before being applicable to human cancer. The article concludes by discussing the kind of correlative research needed to test for and validate predictive biomarkers of tumour fractionation sensitivity.
U2 - 10.1016/j.clon.2015.06.006
DO - 10.1016/j.clon.2015.06.006
M3 - SCORING: Journal article
C2 - 26108884
VL - 27
SP - 570
EP - 578
JO - CLIN ONCOL-UK
JF - CLIN ONCOL-UK
SN - 0936-6555
IS - 10
ER -